Early-Life Gut Microbiota: Education of the Immune System and Links to Autoimmune Diseases

TL;DR

The early-life gut microbiome plays a crucial role in shaping the immune system and may influence the risk of autoimmune diseases later in life.

Contribution

This paper reviews how early-life gut microbiota influences immune maturation and autoimmune disease risk, emphasizing the need for targeted preventive strategies.

Findings

Disruptions in early-life gut microbiota are linked to increased risk of autoimmune diseases like type 1 diabetes and inflammatory bowel disease.

Probiotics and microbiota transplants can partially restore disrupted microbiomes but have not yet prevented autoimmune diseases.

Longitudinal studies are needed to evaluate the impact of microbiome modulation on autoimmune outcomes.

Abstract

Early life is a critical window for immune system development, during which the gut microbiome shapes innate immunity, antigen presentation, and adaptive immune maturation. Disruptions in microbial colonization—driven by factors such as cesarean delivery, antibiotic exposure, and formula feeding—deplete beneficial early-life taxa (e.g., Bifidobacterium, Bacteroides, and Enterococcus) and impair key microbial functions, including short-chain fatty acid (SCFA) production by these keystone species, alongside regulatory T cell induction. These dysbiosis patterns are associated with an increased risk of pediatric autoimmune diseases, notably type 1 diabetes, inflammatory bowel disease, celiac disease, and juvenile idiopathic arthritis. This review synthesizes current evidence on how the early-life microbiota influences immune maturation, with potential effects on the development of autoimmune diseases later in life. We specifically focus on human observational and intervention studies, where treatments with probiotics, synbiotics, vaginal microbial transfer, or maternal fecal microbiota transplantations have been shown to partially restore a disrupted microbiome. While restoration of the gut microbiome composition and function is the main reported outcome of these studies, to date, no reports have disclosed direct prevention of autoimmune disease development by targeting the early-life gut microbiome. In this regard, a better understanding of the early-life microbiome–immune axis is essential for developing targeted preventive strategies. Future research must prioritize longitudinal evaluation of autoimmune outcomes after microbiome modulation to reduce the burden of chronic immune-mediated diseases.

Figures